Advertisement

Langenbeck's Archives of Surgery

, Volume 395, Issue 6, pp 719–726 | Cite as

Osteogenic differentiation of human mesenchymal stromal cells is promoted by a leukocytes containing fibrin matrix

  • Dominik Seybold
  • Thomas A. Schildhauer
  • Jan Geßmann
  • Gert Muhr
  • Manfred Köller
  • Bernd Roetman
Original Article

Abstract

Purpose

Mesenchymal stem cells (multipotent human mesenchymal stromal cells, MSC) are currently the most promising cell type for regenerative medicine. For a clinical approach, it is necessary to develop and establish methods for expansion, differentiation, and delivery.

Methods

A completely autologous plasma clot containing peripheral blood mononuclear cells (PBMC) was tested for the osteopromotive activity towards expanded human mesenchymal stem cells in vitro. The plasma clot was prepared from anticoagulated blood plasma after addition of isolated leukocytes and calcium chloride. Plasma clots after the gelation were added to subconfluently growing MSC or used in a transwell system. Cell proliferation, the activity of alkaline phosphatase, the release of osteoprotegerin, C-terminal procollagen peptide, as well as osteocalcin, the analysis of matrix mineralization as well as bone nodule formation were analyzed up to 3 weeks.

Results

In contrast to plasma clots with no exogenously added leukocytes, the presence of PBMC within the plasma clot significantly promoted osteogenic differentiation of MSC correlated to the time period of incubation. Proliferation of MSC was decreased at maximal mineralization time points. In addition, the osteopromotive activity was identified as soluble factor/factors by transwell assay system. There was a decrease in osteoprotegerin when the cells were cultured in the presence of plasma clots compared to control cell cultures without plasma clots. The osteocalcin expression was continuously higher after culture in the presence of plasma clots and significantly higher after 2- and 3-week after culture in the presence of leukocyte-containing plasma clots compared to 1-week cell culture. Differences in the concentration of the C-terminal procollagen peptide were not measured.

Conclusions

The direct inoculation of an autologous mononuclear cell fraction (which contains leukocytes and MSC), e.g., isolated from a bone marrow aspirate or a different source into an autologous plasma gel, may be a further new strategy for bone fracture therapy.

Keywords

Mesenchymal stem cells Plasma clot Tissue engineering Fracture healing Bone regeneration 

References

  1. 1.
    Kode JA, Mukherjee S, Joglekar MV, Hardikar AA (2009) Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 11:377–391CrossRefPubMedGoogle Scholar
  2. 2.
    Köller M, Schildhauer TA, Kroll V, Fischer K, Muhr G (2005) Ex vivo-Expansion mesenchymaler Stammzellen (MSC) des Knochenmarks mittels geschlossenem Bioreaktor. In: Rothmund M, Jauch K-W, Bauer H (Eds.) Chirurgisches Forum für experimentelle und klinische Forschung, Forum Band 34, XII Tissue Engineering und Angiogenese. Springer, Berlin, pp 353–354Google Scholar
  3. 3.
    Schildhauer TA, Seybold D, Geßmann J, Muhr G, Köller M (2007) Fixation of porous calcium phosphate with expanded bone marrow cells using an autologous plasma clot. Mater Sci Eng Technol 38:1012–1014Google Scholar
  4. 4.
    Catelas I, Sese N, Wu BM, Dunn JC, Helgerson S, Tawil B (2006) Human mesenchymal stem cell proliferation and osteogenic differentiation in fibrin gels in vitro. Tissue Eng 12:2385–2396CrossRefPubMedGoogle Scholar
  5. 5.
    Trombi L, Mattii L, Pacini S, D’Alessandro D, Battolla B, Orciuolo E, Buda G, Fazzi R, Galimberti S, Petrini M (2008) Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. J Orthop Res 26:176–183CrossRefPubMedGoogle Scholar
  6. 6.
    Köller M, Kroll V, Schildhauer TA, Muhr G (2006) Activated leukocytes promote osteogenic differentiation of human mesenchymal stem cells. In: Vollmar B (ed) XLI Congress of the European Society for Surgical Research. Medimond International Proceedings. Bologna, pp 49–52Google Scholar
  7. 7.
    Habijan T, Bremm O, Esenwein SA, Muhr G, Köller M (2007) Influence of nickel ions on human multipotent mesenchymal stromal cells (MSC). Mater Sci Eng Technol 38:969–974Google Scholar
  8. 8.
    English D, Andersen BR (1974) Single-step separation of red blood cells, granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Methods 5:249–252CrossRefPubMedGoogle Scholar
  9. 9.
    Vanella L, Kim DH, Asprinio D, Peterson SJ, Barbagallo I, Vanella A, Goldstein D, Ikehara S, Kappas A, Abraham NG (2009) HO-1 expression increases mesenchymal stem cell-derived osteoblasts but decreases adipocyte lineage. Bone 46:236–243CrossRefPubMedGoogle Scholar
  10. 10.
    Wright HL, McCarthy HS, Middleton J, Marshall MJ (2009) RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2:56–64CrossRefPubMedGoogle Scholar
  11. 11.
    Shi S, Kirk M, Kahn AJ (1996) The role of type I collagen in the regulation of the osteoblast phenotype. J Bone Miner Res 11:1139–1145CrossRefPubMedGoogle Scholar
  12. 12.
    Rifas L, Arackal S, Weitzmann MN (2003) Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. J Cell Biochem 88:650–659CrossRefPubMedGoogle Scholar
  13. 13.
    Rifas L (2006) T-cell cytokine induction of BMP-2 regulates human mesenchymal stromal cell differentiation and mineralization. J Cell Biochem 98:706–714CrossRefPubMedGoogle Scholar
  14. 14.
    Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, Thornton S, Degen JL (2007) Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest 117:3224–3235CrossRefPubMedGoogle Scholar
  15. 15.
    Kastl SP, Speidl WS, Katsaros KM, Kaun C, Rega G, Assadian A, Hagmueller GW, Hoeth M, de Martin R, Ma Y, Maurer G, Huber K, Wojta J (2009) Thrombin induces the expression of oncostatin M via AP-1 activation in human between coagulation and inflammation. Blood 114:2812–2818PubMedGoogle Scholar
  16. 16.
    Rock G, Neurath D, Lu M, Alharbi A, Freedman M (2006) The contribution of platelets in the production of cryoprecipitates for use in a fibrin glue. Vox Sang 91:252–255CrossRefPubMedGoogle Scholar
  17. 17.
    Wrotniak M, Bielecki T, Gaździk TS (2007) Current opinion about using the platelet-rich gel in orthopaedics and trauma surgery. Ortop Traumatol Rehabil 9:227–238PubMedGoogle Scholar
  18. 18.
    Wong C, Inman E, Spaethe R, Helgerson S (2003) Fibrin-based biomaterials to deliver human growth factors. Thromb Haemost 89:573–582PubMedGoogle Scholar
  19. 19.
    Huang NF, Lam A, Fang Q, Sievers RE, Li S, Lee RJ (2009) Bone marrow-derived mesenchymal stem cells in fibrin augment angiogenesis in the chronically infarcted myocardium. Regen Med 4:527–538CrossRefPubMedGoogle Scholar
  20. 20.
    Catelas I, Dwyer JF, Helgerson S (2008) Controlled release of bioactive transforming growth factor beta-1 from fibrin gels in vitro. Tissue Eng Part C Methods 14:119–128CrossRefPubMedGoogle Scholar
  21. 21.
    Mosesson MW (2005) Fibrinogen and fibrin structure and functions. J Thromb Haemost 3:1894–1904CrossRefPubMedGoogle Scholar
  22. 22.
    Agis H, Kandler B, Fischer MB, Watzek G, Gruber R (2009) Activated platelets increase fibrinolysis of mesenchymal progenitor cells. J Orthop Res 27:972–980CrossRefPubMedGoogle Scholar
  23. 23.
    Baumgartner L, Arnhold S, Brixius K, Addicks K, Bloch W (2009) Human mesenchymal stem cells: influence of oxygen pressure on proliferation and chondrogenic differentiation in fibrin glue in vitro. J Biomed Mater Res A (in press)Google Scholar
  24. 24.
    Ho W, Tawil B, Dunn JC, Wu BM (2006) The behavior of human mesenchymal stem cells in 3D fibrin clots: dependence on fibrinogen concentration and clot structure. Tissue Eng 12:1587–1595CrossRefPubMedGoogle Scholar
  25. 25.
    Wolberg AS (2007) Thrombin generation and fibrin clot structure. Blood Rev 21:131–142CrossRefPubMedGoogle Scholar
  26. 26.
    Amelot AA, Tagzirt M, Ducouret G, Kuen RL, Le Bonniec BF (2007) Platelet factor 4 (CXCL4) seals blood clots by altering the structure of fibrin. J Biol Chem 282:710–720CrossRefPubMedGoogle Scholar
  27. 27.
    Deschaseaux F, Sensébé L, Heymann D (2009) Mechanisms of bone repair and regeneration. Trends Mol Med 15:417–429CrossRefPubMedGoogle Scholar
  28. 28.
    Schildhauer TA, Chapman JR, Muhr G, Köller M (2006) Cytokine release of mononuclear leukocytes (PBMC) after contact to a carbonated calcium phosphate bone cement. J Biomed Mater Res 78A:104–109CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Dominik Seybold
    • 1
  • Thomas A. Schildhauer
    • 1
    • 2
  • Jan Geßmann
    • 1
  • Gert Muhr
    • 1
  • Manfred Köller
    • 1
  • Bernd Roetman
    • 1
  1. 1.Chirurgische Klinik und Poliklinik Berufsgenossenschaftliches Universitätsklinikum BergmannsheilRuhr-Universität Bochum Bürkle-de-la-Camp-Platz 1BochumGermany
  2. 2.Universitätsklinik für Unfallchirurgie und SporttraumatologieMedizinische Universität GrazGrazÖsterreich

Personalised recommendations